| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| 25g |
|
||
| Other Sizes |
|
| ln Vitro |
Protein synthesis in cells and E is specifically inhibited by spectinomycin dihydrochloride. Coli extracts: 50 μg/mL of streptomycin dihydrochloride quickly and reversibly inhibits E. coli development and stops the incorporation of amino acids right away [1]. With a maximal inhibition rate of 70-80% in E, spectinomycin diHClide (1 μg/mL or 3 μM) inhibits peptide synthesis directed by endogenous messenger RNA or MS-2 phage RNA. extracted from Coli[1][1]. Spectinomycin dihydrochloride prevents elongation factor G from attaching to the ribosome, hence preventing peptidyl tRNA from translocating from the A site to the P site [2]. Reagents G1064 and 01192 in 16S rRNA are particularly interacting with and may be rendered inactive by streptinomycin diHClide [2]. Due to its dependence on pH variations and Mg2+ concentration, spectinomycin diHClide shows inhibition of splicing, which may indicate electrostatic interactions with intronic RNA [3].
|
|---|---|
| ln Vivo |
It has been demonstrated that in healthy chicks, spectinomycin dihydrochloride (20 mg/kg; IM; 20-100 mg/kg; 9 days) is safe [4]. The majority of the dose of specinomycin dihydrochloride (10 mg/kg; intravenous injection; single dose) is excreted unchanged into the urine by the kidneys [5]. Pharmacokinetics of spectinomycin hydrochloride in rats [5] Parameter C0 (μg/mL) AUC0-∞ (μg·h/mL) Vd (L/kg) CL (L/h/kg) MRT (h) T1/2α (h) T1/2β (h) fe CLrenal (L/h/kg) Eratio non-compartment analysis 44.3 16.8 0.756 0.602 0.757 / / 0.553 0.359 1.00 Three-compartment model 37.8 15.7 0.747 0.649 1.11 / 0.237 0.754 19.5 / /
|
| Animal Protocol |
Animal/Disease Models: Arbor Acres plus broiler chicken (15 days old) [4]
Doses: 20 mg/kg, 60 mg/kg, 100 mg/kg Route of Administration: intramuscularinjection (chest muscle); 9 Day Experimental Results: Complete blood count, biochemical parameters, histopathology, clinical signs, weight gain and feed conversion ratio (FCR) demonstrated biosafety of 20 mg/kg. Produces mild toxicity at 60 mg/kg. |
| References |
[1]. Davies J, et al. Inhibition of protein synthesis by spectinomycin. Science. 1965 Sep 3;149(3688):1096-8.
[2]. Brink MF, et al. Spectinomycin interacts specifically with the residues G1064 and C1192 in 16S rRNA, thereby potentially freezing this molecule into an inactive conformation. Nucleic Acids Res. 1994 Feb 11;22(3):325-31. [3]. Park IK, et al. Spectinomycin inhibits the self-splicing of the group 1 intron RNA. Biochem Biophys Res Commun. 2000 Mar 16;269(2):574-9. [4]. Khan EA, et al. Safety evaluation study of lincomycin and spectinomycin hydrochloride intramuscular injection in chickens. Toxicol Rep. 2022 Jan 29;9:204-209. [5]. Madhura DB, et al. Pharmacokinetic profile of spectinomycin in rats. Pharmazie. 2013 Aug;68(8):675-6. |
| Molecular Formula |
C14H26CL2N2O7
|
|---|---|
| Molecular Weight |
405.2714
|
| CAS # |
21736-83-4
|
| Related CAS # |
Spectinomycin dihydrochloride pentahydrate;22189-32-8;Spectinomycin;1695-77-8
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
Cl[H].Cl[H].O1[C@]2(C(C([H])([H])[C@@]([H])(C([H])([H])[H])O[C@@]2([H])O[C@]2([H])[C@]([H])([C@@]([H])([C@@]([H])([C@@]([H])([C@@]12[H])N([H])C([H])([H])[H])O[H])N([H])C([H])([H])[H])O[H])=O)O[H]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~246.75 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (123.37 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4675 mL | 12.3375 mL | 24.6749 mL | |
| 5 mM | 0.4935 mL | 2.4675 mL | 4.9350 mL | |
| 10 mM | 0.2467 mL | 1.2337 mL | 2.4675 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
